Jun 2026 (Q2 FY26) — Jul 30, 2026
Madrigal Pharmaceuticals Q2 FY26 — Rezdiffra Exceeds Expectations with Strong Patient Adds and Robust Sales Growth
Read the full callMadrigal Pharmaceuticals (MDGL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Madrigal Pharmaceuticals earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 364 | +71.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -15.5 | +6.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -57.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$447.09 −0.59% · −$2.65
Performance +1.9% 1Y
1Y: $438.9 on 17 Oct 2025 → $447.09. High $602.83 (22 Dec 2025), low $412.35 (3 Nov 2025).
- Previous close
- $449.74
- 52-week range
- $412.35 – $602.83
- One year
- +1.62%
Overview
- Symbol
- MDGL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Madrigal Pharmaceuticals Q1 FY26 — Rezdiffra Blockbuster Status & Pipeline Expansion
Read the full callEvery analysed call
Madrigal Pharmaceuticals earnings calls (MDGL)
Financials
What the filings say
Net profit, year on year: −37% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 103 | 137 | 213 | 287 | 321 | 311 | 364 |
| Operating profit | -116 | -67 | -79 | -47 | -114 | -60 | -93 | -56 |
| Operating margin | −187.1% | −64.8% | −57.8% | −22.2% | −39.7% | −18.6% | −29.8% | −15.5% |
| Interest | 4 | 3 | 3 | 3 | 7 | 8 | 8 | 8 |
| Net profit | -107 | -59 | -73 | -42 | -114 | -59 | -94 | -58 |
| EPS ($ per share) | -4.92 | — | -2.61 | -1.50 | -4.01 | — | -3.25 | -1.99 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -139 | -223 | -425 | -667 | -963 | -1,336 | -1,802 | -2,090 |
| Total liabilities | 8 | 25 | 47 | 77 | 165 | 235 | 288 | 657 |
| Fixed assets | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Total assets | 485 | 442 | 287 | 273 | 363 | 641 | 1,042 | 1,260 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26 | -42 | -158 | -184 | -225 | -324 | -456 | -190 |
| Cash from investing | -380 | 31 | 160 | -5 | 207 | -503 | -274 | 32 |
| Cash from financing | 314 | 0 | 5 | 171 | 313 | 595 | 735 | 256 |
| Net cash flow | — | — | — | -18 | 295 | -232 | 5 | 99 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -0 |
| Free cash flow | -26 | -42 | -158 | -184 | -225 | -326 | -457 | -190 |
MDGL revenue by segment
| Segment | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | 100% | +71.2% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
MDGL operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients Rezdiffra | 42.25K+We ended the first quarter with more than 42,250 active patients on Rezdiffra.Source: earnings call transcript | 49K+That's why we've steadily added patients ending the second quarter with more than 49,000 active patients on Rezdiffra, more than double a year ago.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
233 filings between Nov 5, 2025 and Sep 11, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$81.48M
202 sales by 9 insiders
84% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 16
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| FRIEDMAN PAUL A | — | $26.66M | Jan 9, 2026 |
| Taub Rebecca | — | $21.68M | Mar 6, 2026 |
| Sibold William John | — | $10.48M | Sep 11, 2026 |
| BATE KENNETH | — | $8.03M | Nov 5, 2025 |
| Levy Richard S | — | $7.36M | May 22, 2026 |
| Dier Mardi | — | $3.77M | Mar 6, 2026 |
| Huntsman Carole | — | $1.71M | Mar 6, 2026 |
| Soergel David | — | $952.0K | Jun 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 368 | $199.3K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 687 | $371.4K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 761 | $414.6K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 160 | $86.0K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 60 | $32.0K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 218 | $116.8K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 106 | $56.6K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 120 | $65.6K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 1,539 | $837.3K |
| Sep 11, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 1,202 | $652.2K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 160 | $86.8K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 131 | $69.2K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 644 | $344.7K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 396 | $211.5K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 522 | $276.8K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 362 | $196.1K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 512 | $272.9K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 215 | $115.9K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 520 | $279.9K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 505 | $272.8K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 640 | $343.8K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 347 | $183.7K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 1,040 | $557.6K |
| Sep 9, 2026 | Sibold William John President and CEO | Sale 10b5-1 plan | 368 | $195.8K |
| Aug 17, 2026 | Kelley Shannon T General Counsel | Sale | 664 | $341.9K |
| Aug 15, 2026 | REED JOHN C Director | Award | 647 | $0 |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 545 | $296.9K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 110 | $59.8K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 140 | $76.0K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 275 | $150.1K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 1 | $551 |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 680 | $372.4K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 280 | $155.4K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 269 | $147.2K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 153 | $84.2K |
| Jul 20, 2026 | Sibold William John President and CEO | Sale | 47 | $25.8K |
| Jul 17, 2026 | Sibold William John President and CEO | Option exercise | 50,000 | — |
| Jun 17, 2026 | Brennan Daniel J. Director | Award | 404 | $0 |
| Jun 17, 2026 | BAKER BROS. ADVISORS LP Director | Award | 908 | $0 |
| Jun 17, 2026 | Taub Rebecca Director | Award | 454 | $0 |
| Jun 17, 2026 | BAKER BROS. ADVISORS LP Director | Award | 908 | $0 |
| Jun 17, 2026 | Levy Richard S Director | Award | 454 | $0 |
| Jun 17, 2026 | FOUSE JACQUALYN A Director | Award | 454 | $0 |
| Jun 17, 2026 | Daly James M Director | Award | 454 | $0 |
| Jun 1, 2026 | Soergel David Chief Medical Officer | Sale 10b5-1 plan | 1,042 | $516.6K |
| May 22, 2026 | Levy Richard S Director | Sale 10b5-1 plan | 439 | $225.0K |
| May 22, 2026 | Levy Richard S Director | Sale 10b5-1 plan | 610 | $312.0K |
| May 22, 2026 | Levy Richard S Director | Sale 10b5-1 plan | 151 | $77.1K |
| May 22, 2026 | Levy Richard S Director | Sale 10b5-1 plan | 320 | $162.6K |
| May 22, 2026 | Levy Richard S Director | Sale 10b5-1 plan | 40 | $20.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MADRIGAL PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow MADRIGAL PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading